Baillie Gifford & CO Novo Cure LTD Transaction History

Baillie Gifford & CO

$126 Billion
Q1 2024

A detailed history of Baillie Gifford & CO transactions in Novo Cure LTD stock. As of the latest transaction made, Baillie Gifford & CO holds 1,990,375 shares of NVCR stock, worth $34.1 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

1,990,375

Previous 4,840,141 58.88%

Holding current value

$34.1 Million

Previous $72.3 Million 56.95%

% of portfolio

0.02%

Previous 0.06%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 01, 2024	SELL	$12.42 - $17.29 $35.4 Million - $49.3 Million	-2,849,766 Reduced 58.88%	1,990,375 $31.1 Million
Q4 2023 Jan 26, 2024	SELL	$11.13 - $15.78 $22 Million - $31.2 Million	-1,974,073 Reduced 28.97%	4,840,141 $72.3 Million
Q3 2023 Nov 13, 2023	SELL	$16.15 - $42.35 $30.3 Million - $79.5 Million	-1,876,250 Reduced 21.59%	6,814,214 $110 Million
Q2 2023 Jul 28, 2023	BUY	$40.29 - $82.51 $3.5 Million - $7.18 Million	86,963 Added 1.01%	8,690,464 $361 Million
Q1 2023 May 03, 2023	SELL	$56.44 - $118.81 $14.7 Million - $30.9 Million	-260,341 Reduced 2.94%	8,603,501 $517 Million

Q4 2022 Jan 24, 2023	SELL	$63.98 - $85.37 $3.22 Million - $4.3 Million	-50,349 Reduced 0.56%	8,863,842 $650 Million
Q3 2022 Oct 27, 2022	SELL	$67.99 - $89.57 $13.7 Million - $18.1 Million	-202,039 Reduced 2.22%	8,914,191 $677 Million
Q2 2022 Aug 08, 2022	SELL	$56.6 - $89.9 $12.7 Million - $20.2 Million	-224,615 Reduced 2.4%	9,116,230 $634 Million
Q1 2022 May 05, 2022	SELL	$60.15 - $84.52 $16.5 Million - $23.2 Million	-274,323 Reduced 2.85%	9,340,845 $774 Million
Q4 2021 Jan 20, 2022	BUY	$75.08 - $121.99 $18.4 Million - $29.9 Million	245,463 Added 2.62%	9,615,168 $722 Million
Q3 2021 Oct 19, 2021	BUY	$116.17 - $194.55 $7.97 Million - $13.4 Million	68,624 Added 0.74%	9,369,705 $1.09 Billion
Q2 2021 Aug 02, 2021	BUY	$130.4 - $225.58 $57 Million - $98.6 Million	437,149 Added 4.93%	9,301,081 $2.06 Billion
Q1 2021 May 06, 2021	BUY	$124.11 - $190.17 $74.8 Million - $115 Million	602,857 Added 7.3%	8,863,932 $1.17 Billion
Q4 2020 Feb 10, 2021	BUY	$112.16 - $174.14 $15.3 Million - $23.8 Million	136,430 Added 1.68%	8,261,075 $1.43 Billion
Q3 2020 Nov 12, 2020	BUY	$58.05 - $111.31 $12.8 Million - $24.6 Million	220,925 Added 2.8%	8,124,645 $904 Million
Q2 2020 Aug 12, 2020	BUY	$57.2 - $74.41 $9.56 Million - $12.4 Million	167,102 Added 2.16%	7,903,720 $469 Million
Q1 2020 May 08, 2020	SELL	$57.05 - $95.75 $15.5 Million - $26.1 Million	-272,364 Reduced 3.4%	7,736,618 $521 Million
Q4 2019 Feb 10, 2020	SELL	$68.3 - $93.8 $44 Million - $60.5 Million	-644,636 Reduced 7.45%	8,008,982 $675 Million
Q3 2019 Nov 07, 2019	SELL	$61.86 - $97.8 $10.9 Million - $17.2 Million	-175,831 Reduced 1.99%	8,653,618 $647 Million
Q2 2019 Aug 08, 2019	BUY	$42.22 - $63.23 $33.4 Million - $49.9 Million	789,924 Added 9.83%	8,829,449 $558 Million
Q1 2019 May 01, 2019	BUY	$31.96 - $56.12 $113 Million - $199 Million	3,541,001 Added 78.71%	8,039,525 $0
Q4 2018 Feb 14, 2019	BUY	$28.72 - $52.63 $27.9 Million - $51.1 Million	971,424 Added 27.54%	4,498,524 $151 Million
Q3 2018 Nov 13, 2018	BUY	$32.0 - $52.4 $13.9 Million - $22.7 Million	433,705 Added 14.02%	3,527,100 $185 Million
Q2 2018 Jul 17, 2018	BUY	$19.85 - $32.0 $6.82 Million - $11 Million	343,756 Added 12.5%	3,093,395 $96.8 Million
Q1 2018 May 10, 2018	BUY	$19.3 - $23.65 $41.4 Million - $50.7 Million	2,145,522 Added 355.15%	2,749,639 $59.9 Million
Q4 2017 Feb 13, 2018	BUY	$16.3 - $21.9 $9.85 Million - $13.2 Million	604,117	604,117 $12.2 Million

Others Institutions Holding NVCR

# of Institutions

277

Shares Held

73.2M

Call Options Held

1.43M

Put Options Held

832K

View Full List

About NovoCure Ltd

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $1.8B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

More about NVCR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Baillie Gifford & CO, based on Form 13F filings with the SEC.

News

Stay updated on Baillie Gifford & CO with notifications on news.

Account

Baillie Gifford & CO Novo Cure LTD Transaction History